Fc-Engineering for Modulated Effector Functions—Improving …
By delivering Fc-Fc gamma receptor (FcγR) and Fc-C1q interactions, mAb are able to link exquisite specificity to powerful cellular and complement-mediated effector functions. Fc …
单克隆抗体结构与作用机理-单抗简介-单克隆抗体专题-南京德泰生物
mAb的生物学功能主要是由其结构决定。抗体由抗原结合域（Fab）和结晶区域（Fc）组成，Fab主要特异性识别肿瘤相关抗原，进而调控下游的信号通路。Fc可以识别并结合表达Fc受 …
The Role of Fc Receptors on the Effectiveness of Therapeutic …
Optimized FcγR-mediated effector functions regarding clinical safety and efficacy are addressed with modification strategies such as point mutations, altered glycosylation patterns, …
Pharmacokinetics of monoclonal antibodies and Fc-fusion …
Antibody derivatives include Fc-fusion proteins, antibody-drug conjugates (ADCs), immunocytokines (antibody-cytokine fusions), and antibody-enzyme fusions. The efficacy of a …
Boosting therapeutic potency of antibodies by taming Fc …
2019年11月18日 · Antibodies bind to pathogens or cancer cells, flagging them with Fc (fragment crystallizable) domain for destruction by the immune system. mAbs attached only to specific …
The Role of Fc Receptors on the Effectiveness of Therapeutic
2021年8月19日 · The α-C5 mAb eculizumab is the first approved cross-isotype mAb, which has the amino acids 118–260 of IgG2 and the amino acids 261–447 of IgG4 resulting in limited or …
单克隆抗体和Fc融合蛋白的药代动力学,Protein & Cell - X-MOL
通过Fab或Fc工程，IgG-FcRn相互作用可用于产生多种治疗性抗体，这些抗体的半衰期显着延长或具有从循环中去除不需要的抗原的能力。 mAb或Fc融合蛋白的糖基化可能对这些分子的PK产 …
Fc-Engineered Therapeutic Antibodies: Recent Advances and …
Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …
Fc receptor-dependent mechanisms of monoclonal antibody therapy …
Direct mechanisms of action, including induction of apoptosis or growth inhibition, depend on the biology of the target antigen. Fc tails of mAbs have furthermore the potential to initiate …
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
2017年4月19日 · There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being FcRn-mediated recycling. Through …